Mergers & Acquisitions ·
GSK plc announced a tender offer to acquire Nuvalent, Inc. for $124.00 per share in cash
GSKGSK plc
GSK plc announced a tender offer to acquire Nuvalent, Inc. for $124.00 per share in cash. The acquisition is being conducted through a wholly-owned subsidiary, Harmony Row Acquisition Co., and is subject to a majority tender condition and antitrust regulatory approval. Nuvalent's Board of Directors has recommended that stockholders accept the offer, which expires on July 14, 2026. GSK is a global biopharma company focused on disease prevention and treatment.